Moesin Expression in Clear Cell Renal Cell Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes. Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire some mesenchymal criteria as enhanced invasive potential. There are several cell surface molecules that are implicated in EMT. Moesin is one of these molecules that is involved in EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with RCC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Studying Gene Expression in Samples From Patients With Rhabdoid Tumors

NCT01553175

Brain and Central Nervous System Tumors Kidney Cancer

COMPLETED

Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients

NCT06778538

Clear Cell Renal Cell Carcinoma (ccRCC)

COMPLETED

microRNA Expression in Renal Cell Carcinoma

NCT00743054

Carcinoma, Renal Cell

COMPLETED

Tertiary Lymphoid Structures Related Genes Predicting Prognosis in Clear Cell Renal Cell Carcinoma: a Retrospective Cohort Study

NCT06883565

Renal Cell Carcinoma (RCC)

COMPLETED

Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer

NCT00908739

Kidney Cancer

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma

Formalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. All cases of ccRCC.
2. Tissue blocks with material adequate for immunohistochemical evaluation.
3. All cases with accessible clinical data.

Exclusion Criteria

1. Cases of renal neoplasms other than ccRCC.
2. Patients who received preoperative chemotherapy or radiotherapy.
3. Patients with ccRCC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations.
4. Cases with insufficient/destructed material.
5. Patients with inadequate clinical data.

Eligible Sex

ALL

Accepts Healthy Volunteers

No